Joel Sheinfeld

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Stage I testicular cancer management and necessity for surgical expertise
    Joel Sheinfeld
    J Clin Oncol 26:2934-6. 2008
  2. ncbi request reprint Paracolic recurrence: the importance of wide excision of the spermatic cord at retroperitoneal lymph node dissection
    Sam S Chang
    Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    J Urol 167:94-6. 2002
  3. ncbi request reprint Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors
    Joel Sheinfeld
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 170:1159-62. 2003
  4. ncbi request reprint Reoperative retroperitoneal surgery
    Joel Sheinfeld
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urol Clin North Am 34:227-33; abstract x. 2007
  5. ncbi request reprint Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 25:5597-602. 2007
  6. ncbi request reprint Mapping studies and modified templates in nonseminomatous germ cell tumors
    Joel Sheinfeld
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 353 East 68th Street, New York, NY 10021, USA
    Nat Clin Pract Urol 4:60-1. 2007
  7. ncbi request reprint Impact of unnecessary exploratory laparotomy on the treatment of patients with metastatic germ cell tumor
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 171:1474-7. 2004
  8. doi request reprint Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer
    Timothy A Masterson
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urology 79:156-9. 2012
  9. pmc The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer
    Brett S Carver
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 75:1431-5. 2010
  10. doi request reprint Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site
    Timothy A Masterson
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 79:1079-84. 2012

Detail Information

Publications74

  1. doi request reprint Stage I testicular cancer management and necessity for surgical expertise
    Joel Sheinfeld
    J Clin Oncol 26:2934-6. 2008
  2. ncbi request reprint Paracolic recurrence: the importance of wide excision of the spermatic cord at retroperitoneal lymph node dissection
    Sam S Chang
    Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    J Urol 167:94-6. 2002
    ..We evaluated ipsilateral spermatic cord metastatic involvement at retroperitoneal lymph node dissection and identified the possible etiology of these unusual recurrences...
  3. ncbi request reprint Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors
    Joel Sheinfeld
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 170:1159-62. 2003
    ..We determined the incidence and clinical outcome of patients with clinical stages I and IIA nonseminomatous germ cell tumors (NSGCT), and teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection (RPLND)...
  4. ncbi request reprint Reoperative retroperitoneal surgery
    Joel Sheinfeld
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urol Clin North Am 34:227-33; abstract x. 2007
    ..The integration of chemotherapy and reoperative surgery can result in survival rates of almost 70% in patients with retroperitoneal relapse after initial suboptimal RPLND...
  5. ncbi request reprint Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 25:5597-602. 2007
    ..3). CONCLUSION Patient selection factors have significantly improved the outcome of patients with CS IIA and IIB NSGCT without substantially increasing the proportion of patients exposed to chemotherapy...
  6. ncbi request reprint Mapping studies and modified templates in nonseminomatous germ cell tumors
    Joel Sheinfeld
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 353 East 68th Street, New York, NY 10021, USA
    Nat Clin Pract Urol 4:60-1. 2007
  7. ncbi request reprint Impact of unnecessary exploratory laparotomy on the treatment of patients with metastatic germ cell tumor
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 171:1474-7. 2004
    ..In a cohort of patients who underwent exploratory laparotomy for unsuspected metastatic GCT we determined the impact of this surgery on morbidity, therapeutic delay and cancer therapy...
  8. doi request reprint Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer
    Timothy A Masterson
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urology 79:156-9. 2012
    ..We reviewed our institutional experience in patients undergoing resection of extraretroperitoneal (ERP) residual masses after chemotherapy to assess its impact on cancer progression and survival...
  9. pmc The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer
    Brett S Carver
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 75:1431-5. 2010
    ..After the multidisciplinary management of metastatic germ cell tumor, approximately 10%-15% of patients with the histologic finding of fibrosis or teratoma will suffer disease recurrence...
  10. doi request reprint Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site
    Timothy A Masterson
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 79:1079-84. 2012
    ..To compare the survival outcomes of patients with advanced nonseminoma and extraretroperitoneal (ERP) disease observed for a clinical complete response (CCR) with those demonstrating a pathologic complete response (PCR)...
  11. ncbi request reprint Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour
    Bobby Shayegan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 99:993-7. 2007
    ....
  12. ncbi request reprint Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy
    G Varuni Kondagunta
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 22:464-7. 2004
    ....
  13. ncbi request reprint Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma
    Brett S Carver
    Department of Urology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 25:1033-7. 2007
    ..We evaluated patients at our institution undergoing initial PC-RPLND for teratoma to determine their clinical outcome...
  14. pmc TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis
    Darren R Feldman
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 28:1706-13. 2010
    ..We now report the efficacy of TI-CE with prognostic factors for disease-free survival (DFS) and overall survival (OS) in our full data set of 107 patients...
  15. ncbi request reprint Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome
    James M McKiernan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 62:732-6. 2003
    ....
  16. ncbi request reprint Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:6549-55. 2005
    ..The efficacy of paclitaxel was evaluated in combination with ifosfamide and cisplatin as second-line chemotherapy for patients with relapsed testicular germ cell tumors (GCTs)...
  17. pmc Clinical outcome and predictors of survival in late relapse of germ cell tumor
    David S Sharp
    Department of Urology, Memorial Sloan Kettering Cancer Center, 353 E 68th St, New York, NY 10021, USA
    J Clin Oncol 26:5524-9. 2008
    ..Late relapse (LR) of germ cell tumor (GCT) is a well recognized entity associated with poor survival. We report on our experience with LR and determine predictors of survival...
  18. ncbi request reprint Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors
    Brett S Carver
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, 353 E 68th St, New York, NY 10021, USA
    J Clin Oncol 25:5603-8. 2007
    ..We evaluated men undergoing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for NSGCT to determine associations between year of treatment and clinical outcome...
  19. ncbi request reprint Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection
    Brett S Carver
    Department of Urology and Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 25:4365-9. 2007
    ..We evaluated our experience with PC-RPLND to determine the incidence of disease extending outside the boundaries of a modified PC-RPLND...
  20. doi request reprint The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor
    Atreya Dash
    Department of Urology and Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 112:800-5. 2008
    ..The objectives of the current study were to determine the clinical outcome, patterns of relapse, and incidence of teratoma in the retroperitoneum for men with cIS NSGCT...
  21. ncbi request reprint Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers and Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 174:557-60; discussion 560. 2005
    ....
  22. doi request reprint Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection
    R Houston Thompson
    Department of Surgery Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Urology 79:361-4. 2012
    ..Lymph node counts are a proposed measure of quality assurance for numerous malignancies. Investigation of patient factors associated with lymph node counts are lacking...
  23. doi request reprint Medical treatment of advanced testicular cancer
    Darren R Feldman
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    JAMA 299:672-84. 2008
    ..Clinicians need to be familiar with the available treatment regimens for testicular cancer and their associated toxic effects...
  24. ncbi request reprint Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy
    Ellen A Ronnen
    Department of Medicine, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:6999-7004. 2005
    ..To define the incidence, clinical features, and outcome to salvage chemotherapy in patients with late-relapse germ cell tumor (GCT) after a complete response to first-line chemotherapy...
  25. ncbi request reprint Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma
    Farhang Rabbani
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 62:1092-6. 2003
    ..To determine the pathologic findings and clinical outcome of patients with pure teratoma of the testis who underwent primary or postchemotherapy retroperitoneal lymphadenectomy (RPLND)...
  26. doi request reprint Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older
    Darren R Feldman
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 119:2574-81. 2013
    ..Germ cell tumors (GCTs) primarily affect adolescent and young adult men. Detailed clinical and treatment characteristics in older men are lacking...
  27. ncbi request reprint Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 23:9290-4. 2005
    ....
  28. ncbi request reprint Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Epidemiology and Biostatistics, The Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:2729-34. 2006
    ..The aim of this phase II study was to determine the efficacy of gemcitabine administered as an intravesical agent in patients with bacille Calmette-Guérin (BCG) -refractory transitional cell carcinoma of the bladder...
  29. ncbi request reprint Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors
    Scott E Eggener
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 109:528-35. 2007
    ..The authors assessed their institutional experience of retroperitoneal lymph node dissection (RPLND) after multiple chemotherapy regimens for advanced GCT...
  30. doi request reprint Contemporary lymph node counts during primary retroperitoneal lymph node dissection
    R Houston Thompson
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Urology 77:368-72. 2011
    ..We report our contemporary single-surgeon experience with lymph node counts during primary RPLND for nonseminomatous germ cell tumors...
  31. ncbi request reprint Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer
    Scott E Eggener
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:937-42; discussion 942-3. 2007
    ..We evaluated the incidence, sites and histology of disease outside 5 modified retroperitoneal lymph node dissection templates for patients with low stage nonseminomatous germ cell tumors of the testis...
  32. doi request reprint Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update
    Amit Gupta
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Urology 77:655-9. 2011
    ..To examine histologic findings and clinical outcomes of patients who underwent neck dissection for residual neck masses...
  33. doi request reprint Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design
    Darren R Feldman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 118:981-6. 2012
    ..The identification of novel active agents may be impaired by use of response as the primary endpoint in phase 2 trials. Improved endpoints could enhance the development of new effective agents...
  34. doi request reprint The role of lymphadenectomy for testicular cancer: indications, controversies, and complications
    Tatum Tarin
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Urol Clin North Am 38:439-49, vi. 2011
    ..This article discusses the surgical management of testicular cancer, specifically addressing the indications, controversies, and complications of retroperitoneal lymph node dissection for both low-stage and high-stage disease...
  35. ncbi request reprint Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors
    G Varuni Kondagunta
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 22:177-9. 2004
    ..No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients...
  36. ncbi request reprint Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors
    G Varuni Kondagunta
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:85-90. 2007
    ..This prospective trial followed a similarly designed report of TICE, which used a different means of carboplatin dosing...
  37. ncbi request reprint Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:2781-8. 2005
    ..Since 1999, our criteria have excluded patients with persistent postorchiectomy elevation of serum tumor markers (STM) or clinical stage (CS) IIB disease from RPLND...
  38. ncbi request reprint Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection
    Brett S Carver
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 176:100-3; discussion 103-4. 2006
    ..We evaluated patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell tumors to determine predictors of teratomatous elements in the retroperitoneum...
  39. doi request reprint Management of post-chemotherapy extra-retroperitoneal residual masses
    Brett S Carver
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    World J Urol 27:489-92. 2009
    ..While the retroperitoneum is often the first and only site of metastatic disease, approximately 40% of patients presenting with metastatic disease will have disease involving extra-retroperitoneal sites...
  40. doi request reprint Evaluation of lymph node counts in primary retroperitoneal lymph node dissection
    R Houston Thompson
    Department of Surgery Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer 116:5243-50. 2010
    ..Lymph node counts are a measure of quality assurance and are associated with prognosis for numerous malignancies. To date, investigations of lymph node counts in testis cancer are lacking...
  41. doi request reprint Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour
    Timothy A Masterson
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 110:950-5. 2012
    ..Our results showed similar clinical and pathological characteristics, and survival outcomes that compare favourably with those of men aged <50 years...
  42. ncbi request reprint Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors
    Darren R Feldman
    Genitourinary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Invest New Drugs 25:487-90. 2007
    ..For patients who had previously received taxane therapy, ixabepilone was not efficacious in the treatment of cisplatin-refractory GCT...
  43. doi request reprint Retroperitoneal histologic findings of patients with elevated serum alpha-fetoprotein and pure seminoma at orchiectomy
    Shilajit D Kundu
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Urology 78:844-7. 2011
    ..These patients underwent treatment on the assumption that the lesion was nonseminomatous germ cell tumor (NSGCT)...
  44. ncbi request reprint Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis
    Kamal S Pohar
    Department or Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 170:1155-8. 2003
    ..We determined the pathological findings and clinical outcome of patients with pure embryonal carcinoma (EC) of the testis managed by primary retroperitoneal lymph node dissection...
  45. ncbi request reprint The role of retroperitoneal lymph node dissection in the management of testicular cancer
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Urol Oncol 22:225-33; discussion 234-5. 2004
    ..This article reviews the role of RPLND in the management of patients with NSGCT at all stages and its role in advanced seminoma...
  46. ncbi request reprint Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma
    Michael Mullerad
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 172:2177-81. 2004
    ..Overall 5-year disease specific survival is in the range of 16.5% to 95% depending on stage. In this study we evaluated predictors associated with disease recurrence and disease specific survival...
  47. doi request reprint Cervical metastasis of germ cell tumors: evaluation, management, complications, and outcomes
    Saral Mehra
    Department of Otorhinolaryngology Head and Neck Surgery, New York Presbyterian Hospital Weill Cornell Medical College, New York, New York 10065, USA
    Laryngoscope 122:286-90. 2012
    ..This article reports on 34 consecutive patients with GCT metastatic to the neck...
  48. ncbi request reprint The current status of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ-cell tumors
    Brett S Carver
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, USA
    Nat Clin Pract Urol 2:330-5. 2005
    ..Future prospective internal review board-approved trials need to be developed to evaluate the therapeutic efficacy of laparoscopic RPLND, with careful observation of patients with pathologic low-volume nodal disease...
  49. ncbi request reprint Late relapse of testicular germ cell tumors
    Brett S Carver
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urol Oncol 23:441-5. 2005
    ..In this review, we present the recent data regarding the clinical presentation, patterns of relapse, histologic findings, appropriate treatment options, and outcomes for men with late relapse of germ cell tumors...
  50. ncbi request reprint Chemotherapy for teratoma with malignant transformation
    Alessia C Donadio
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 21:4285-91. 2003
    ..We report that chemotherapy has a role in selected patients with MT, determined by cell type...
  51. pmc Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer
    Joseph A Pettus
    Department of Surgery, Division of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 73:328-31; discussion 331-2. 2009
    ..To evaluate the clinical parameters associated with the recovery of ejaculation after nerve-sparing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for nonseminomatous germ cell tumor...
  52. ncbi request reprint Management of patients with low-stage nonseminomatous germ cell testicular cancer
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Treat Options Oncol 6:367-77. 2005
    ....
  53. ncbi request reprint Germ cell tumors of the testis
    Brett S Carver
    Department of Urology, Memorial Sloan Kettering Cancer Center, 353 East 68th Street, New York 10021, USA
    Ann Surg Oncol 12:871-80. 2005
    ..This review summarizes the principal management of germ cell tumors of the testis, highlighting the indications for surgery, controversies surrounding the integration of surgery, and alternative management strategies...
  54. ncbi request reprint Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 176:1996-9; discussion 1999. 2006
    ..We reviewed our experience with adjunctive nephrectomy to assess the impact on cancer control and renal function...
  55. ncbi request reprint Histology and clinical outcomes in patients with bilateral testicular germ cell tumors: the Memorial Sloan Kettering Cancer Center experience 1950 to 2001
    Jeffrey M Holzbeierlein
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 169:2122-5. 2003
    ..The optimal management of bilateral testicular tumors continues to evolve. We examined the incidence, characteristics, histology, treatment and clinical outcomes of patients with bilateral testicular cancer...
  56. ncbi request reprint Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors
    Stephen D W Beck
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 171:168-71. 2004
    ..We report the concentration of alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG) in the fluid of post-chemotherapy cystic masses to evaluate this as a potential source for serum marker elevation...
  57. ncbi request reprint Management of recurrence and follow-up strategies for patients with seminoma and selected high-risk groups
    Manish I Patel
    Department of Urology, Memorial Sloan Kettering Cancer Center, 353 E 68th Street, New York, NY 10021, USA
    Urol Clin North Am 30:803-17. 2003
    ..Patients with seminoma need long-term follow-up because of the possibility of late recurrence and the risk of a second primary tumor...
  58. ncbi request reprint Recommendations of follow-up after treatment of germ cell tumors
    G Varuni Kondagunta
    Department of Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Semin Oncol 30:382-9. 2003
    ..Optimal means of imaging and frequency of physician visits and serum marker level measurements need to be further addressed...
  59. ncbi request reprint Adult and pediatric testicular teratoma
    Brett S Carver
    Department of Urology and Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urol Clin North Am 34:245-51; abstract x. 2007
    ....
  60. ncbi request reprint Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder
    Guido Dalbagni
    Department of Urology, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 20:3193-8. 2002
    ..The aim of this phase I study was to determine the safety and toxicity profile of gemcitabine administered as an intravesical agent in patients with transitional-cell carcinoma (TCC) of the bladder...
  61. doi request reprint Retroperitoneal lymph node dissection (RPLND)
    Oliver Zivanovic
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Gynecol Oncol 111:S66-9. 2008
    ..In the following article we outline the surgical anatomy and describe the essential steps of the RPLND...
  62. ncbi request reprint The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies
    Joel Sheinfeld
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Urol Oncol 20:262-71. 2002
    ..Surgical boundaries and completeness of dissection should not be compromised in an attempt to preserve ejaculation...
  63. ncbi request reprint Salvage chemotherapy for patients with advanced pure seminoma
    Jacqueline Vuky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 20:297-301. 2002
    ..We describe the response to conventional or high-dose salvage chemotherapy in patients with advanced seminoma who experience disease progression after receiving first-line platinum-based treatment...
  64. doi request reprint Postchemotherapy surgery for germ cell tumors of the testis
    Brett S Carver
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Curr Opin Oncol 23:271-4. 2011
    ..To summarize the surgical management of metastatic germ cell tumors of the testis, highlighting the indications for surgery and controversies surrounding the integration of surgery...
  65. doi request reprint Environmental toxicology of testicular cancer
    Joshua J Meeks
    Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Urol Oncol 30:212-5. 2012
    ..In many regions, industrialization results in the production of potentially carcinogenic environmental toxins. We review the available data linking environmental toxins to testicular germ cell tumors (TGCT)...
  66. pmc Critical elements in fellowship training
    R Houston Thompson
    Urology Service, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Urol Oncol 27:199-204. 2009
    ..As an example, the Memorial Sloan-Kettering Cancer Center experience is outlined in detail, including the clinical experience, research curriculum, laparoscopic and minimally invasive exposure, and didactic lecture series...
  67. pmc Surgery for retroperitoneal relapse in the setting of a prior retroperitoneal lymph node dissection for germ cell tumor
    Geoffrey T Gotto
    Department of Urology, Memorial Sloan Kettering Cancer Center, Weill College of Medicine, New York, USA
    Indian J Urol 26:102-7. 2010
    ..Patients with retroperitoneal relapse following initial RPLND should be treated with reoperative RPLND and chemotherapy and can expect long term survival rates nearing 70% when treated in tertiary centers by experienced surgeons...
  68. ncbi request reprint Association between sarcoidosis and testicular carcinoma: a diagnostic pitfall
    Philippe Paparel
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
    Sarcoidosis Vasc Diffuse Lung Dis 24:95-101. 2007
    ....
  69. ncbi request reprint Is there an increased incidence of contralateral testicular cancer in patients with intratesticular microlithiasis?
    Ariadne M Bach
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    AJR Am J Roentgenol 180:497-500. 2003
    ..The objective of this study was to determine if there is an association between intratesticular microlithiasis and contralateral testicular cancer...
  70. ncbi request reprint Risks of the uncontrolled retroperitoneum
    Joel Sheinfeld
    Ann Surg Oncol 10:100-1. 2003
  71. ncbi request reprint Testicular cancer. Clinical practice guidelines in oncology
    Robert J Motzer
    J Natl Compr Canc Netw 4:1038-58. 2006
  72. ncbi request reprint Kidney cancer. Clinical practice guidelines in oncology
    Robert J Motzer
    J Natl Compr Canc Netw 4:1072-81. 2006
  73. ncbi request reprint Prolonged survival following salvage surgery for chemorefractory ovarian immature teratoma: a case report and review of the literature
    Youssef Rezk
    Department of Obstetrics and Gynecology, Albany Medical College, Albany, NY 12208, USA
    Gynecol Oncol 96:883-7. 2005
    ..In this report, a case of advanced IT that was salvaged by secondary cytoreduction following failure of both primary therapy and salvage chemotherapy is described, and the available literature is reviewed...
  74. ncbi request reprint Editorial: predicting necrosis after chemotherapy for advanced nonseminomatous germ cell tumor-surrogate end points, decreasing morbidity and patient outcome
    Joel Sheinfeld
    J Urol 171:1842-3. 2004